C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Total Voting Rights

1 September 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, the Company's issued share capital consists of 252,227,097 ordinary shares.

The above figure of 252,227,097 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- Ends -

Contacts

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation.  Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.